Akintunde Bello
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Akintunde Bello has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Amit Roy
Bristol Myers Squibb Princeton New Jersey USA
46 shared publications - Karen Miller-Moslin
Bristol Myers Squibb, Princeton, New Jersey
45 shared publications - Paul Statkevich
Bristol-Myers Squibb, Princeton, New Jersey
45 shared publications - Sai Praneeth Bathena
Bristol-Myers Squibb, Princeton, New Jersey
45 shared publications - Sarah Keidel
Bristol Myers Squibb, Princeton, New Jersey
45 shared publications - Satyendra Suryawanshi
Clinical Pharmacology, Oncology, Bristol Myers Squibb, Princeton, NJ, USA
45 shared publications
Latest Publications
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Distribution of Predicted Nivolumab Exposures at 480 mg Q4W for Adult ADA+ and ADA- Patients Treated with Relatlimab Plus Nivolumab
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Distribution of Predicted Nivolumab Exposures at 480 mg Q4W for Adult ADA+ and ADA- Patients Treated with Relatlimab Plus Nivolumab
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Predicted Relatlimab Exposures at 160 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adults
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Predicted Relatlimab Exposures at 160 mg Q4W (Relatlimab Plus Nivolumab) by Body Weight Quartiles in Adults
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Prediction-Corrected Visual Predictive Check of a) Relatlimab Concentrations versus Actual Time after Previous Dose and b) Relatlimab trough concentrations versus actual time after first dose in 1L MEL and Prior-IO MEL Patients Who Received 80 mg Q2W and 160 mg Q4W Dosing Regimen (Full Population Pharmacokinetic Model)
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Prediction-Corrected Visual Predictive Check of a) Relatlimab Concentrations versus Actual Time after Previous Dose and b) Relatlimab trough concentrations versus actual time after first dose in 1L MEL and Prior-IO MEL Patients Who Received 80 mg Q2W and 160 mg Q4W Dosing Regimen (Full Population Pharmacokinetic Model)
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Parameter Estimates of the Full Relatlimab Population Pharmacokinetic Model
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Parameter Estimates of the Full Relatlimab Population Pharmacokinetic Model
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Predicted Relatlimab Exposures at 160 mg Q4W 30-Minute Infusion and 60-Minute Infusion in Adult Patients Treated with Relatlimab Plus Nivolumab
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Predicted Relatlimab Exposures at 160 mg Q4W 30-Minute Infusion and 60-Minute Infusion in Adult Patients Treated with Relatlimab Plus Nivolumab
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Parameter Estimates of the Full Relatlimab Population Pharmacokinetic Model
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Parameter Estimates of the Full Relatlimab Population Pharmacokinetic Model
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Model Predicted Change in Relatlimab Clearance versus Time by Patient Population
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Model Predicted Change in Relatlimab Clearance versus Time by Patient Population
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Predicted Nivolumab Exposures for Adolescent Patients and Adult Patients with 1L MEL at 480 mg FDC Q4W
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Predicted Nivolumab Exposures for Adolescent Patients and Adult Patients with 1L MEL at 480 mg FDC Q4W
- Open Access
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Summary of Covariates in the Nivolumab Population Pharmacokinetic Analysis Dataset by Patient Population
- 15 July 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors
Summary of Covariates in the Nivolumab Population Pharmacokinetic Analysis Dataset by Patient Population